(Q46835939)

English

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

scientific article published on 17 November 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Dagmar Kubitza

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

Michael Becka

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

Georg Wensing

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

Barbara Voith

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

Michael Zuehlsdorf

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

publication date

17 November 2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

European Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

61

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

12

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

873-880

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

https://scigraph.springernature.com/pub.10.1007/s00228-005-0043-5

0 references

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current options in the prevention of thromboembolic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New anticoagulants and their potential impact on the treatment of thromboembolic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transaminase elevation on placebo during phase I trials: prevalence and significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/16328318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00228-005-0043-5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16328318

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46835939&oldid=2143631361"